IMAGING CORE: NAPS2 DaT Core

Overview

About this study

The objectives of this study are:

To conduct research on RBD as a prodromal manifestation of DLB, PD, and MSA to address several of the NAPA ADRD priorities for LBD research as well as similar priorities for PD and MSA. Investigate RBD occurring in prodromal synucleinopathy.
To enroll RBD participants and matched control participants for longitudinal, standardized collection of clinical, PSG, genetic, biofluid, and neuroimaging data.
To analyze collected data against longitudinal clinical outcomes to refine scales and develop /analyze biomarkers to optimally design clinical trials.
To share data, samples, and methods for use by the scientific community.
To interact with NIH, other scientific groups on RBD and overt synucleinopathies, industry partners, patients, and other groups.
To prepare for large-scale clinical trials.

The Neuroimaging Core is responsible for imaging operations at 10 NAPS sites, Harmonization and maintenance of the DaTscan protocols, quality control and storage of the imaging data, analysis and sharing of the imaging data.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Val Lowe, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Val Lowe, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials